Eli Lilly reported 52-week results from the TOGETHER-PsO and TOGETHER-PsA studies evaluating the concomitant use of Taltz (ixekizumab) plus Zepbound (tirzepatide) versus Taltz alone in adults with moderate-to-severe plaque psoriasis. The article does not provide efficacy/safety effect sizes, limiting immediate inference on incremental benefit beyond the 52-week dataset.
Eli Lilly reported 52-week results from the TOGETHER-PsO and TOGETHER-PsA studies evaluating the concomitant use of Taltz (ixekizumab) plus Zepbound (tirzepatide) versus Taltz alone in adults with moderate-to-severe plaque psoriasis. The article does not provide efficacy/safety effect sizes, limiting immediate inference on incremental benefit beyond the 52-week dataset.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
